Genmab to sell U.S. plant, cut jobs
Genmab announced a restructuring plan that includes selling its U.S. production plant and laying off about 300 workers. The Danish biotech firm said it will not stop developing pipeline drugs but will "adopt a more flexible model based on contracts with vendors to address varying demand for clinical development work going forward."
Wall Street Journal, The | 11/05
This story published in BIO SmartBrief on 11/06/2009
More from SmartBrief:
LEO Pharma to purchase Peplin for $287.5 million
Thursday, September 3, 2009
GSK, Vernalis in cancer deal potentially worth $200M
Thursday, August 6, 2009
Bristol-Myers completes purchase of Medarex
Wednesday, September 2, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|